Buy or sell Vedanta Biosciences stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies

Vedanta Biosciences Stock
Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome.
About Vedanta Biosciences Stock
Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. Vedanta Biosciences’ proprietary approach leverages foundational discoveries in the field of mucosal immunology to generate safe and potent treatments that restore intestinal homeostasis acting via mechanisms that are orthogonal to all existing drug classes. By modulating the microbiome with this class of drugs, we have the opportunity to treat a range of autoimmune and inflammatory diseases in potentially new ways and impact the lives of patients.
Funding History
June 2016 | $50.0M |
---|---|
November 2017 | $5.4M |
Management
Scientific Co-Founder
Dan Littman
Scientific Co-Founder
Alexander Rudensky
Chief Executive Officer
Bernat Olle
Co-founder
David Steinberg
Co-Founder & Chair
Ruslan Medzhitov
Press
Business Wire (press release) - May, 30 2018
IBD News Today - Dec, 15 2017
Business Wire (press release) - Dec, 7 2017
Business Wire (press release) - Nov, 3 2017
FierceBiotech - Aug, 11 2016
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase